Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
64.27
+0.19 (+0.30%)
Official Closing Price
Updated: 4:15 PM EDT, May 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
30
31
Next >
Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says
December 20, 2022
Via
Benzinga
Why Is Gilead Sciences Stock Sliding Tuesday?
December 20, 2022
Gilead Sciences Inc (NASDAQ: GILD) shares are trading lower Tuesday after the company reported results from its Phase 2 non-small
Via
Benzinga
Arcus, Gilead Disappoint As Lung-Cancer Regimen Lags Rival Roche
December 20, 2022
Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche.
Via
Investor's Business Daily
Gilead-Arcus Partnered Domvanalimab Combo Study Show Improved Progression-Free Survival In Lung Cancer Patients
December 20, 2022
Via
Benzinga
Tuesday Talk: Where is Santa?
December 20, 2022
Monday continued the downtrend for the major indices on Wall Street which concluded a second week of losses on Friday. As for an annual Santa rally, that seems nowhere to be found.
Via
Talk Markets
Could Gilead (GILD) Continue On The Bull Run?
December 17, 2022
Using the Wycoff trading method, we see that Gilead Sciences, Inc (GILD) will likely continue its bullish momentum.
Via
Talk Markets
Beat the Dow Jones With This Unstoppable Dividend Stock
December 12, 2022
Gilead Sciences is a 2022 winner that could stay hot in 2023.
Via
The Motley Fool
Why Is Arcellx (ACLX) Stock Up 25% Today?
December 09, 2022
ACLX stock is usually under the radar, but today it's in the spotlight as Arcellx reveals a team-up with a well-known biotech business.
Via
InvestorPlace
Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro
December 19, 2022
The biotech sector has not done well in 2022 despite some strong runs. Small and mid-cap stocks are more “risk-off’ with interest rates rising and sentiment waning.
Via
Talk Markets
Why Merck's $250 Million Investment In Moderna May Have Just Paid Off
December 13, 2022
Merck opted into Moderna's cancer vaccine. Now, the companies have Phase 2 data.
Via
Investor's Business Daily
Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences
December 09, 2022
The company inked a deal worth $325 million and up to $3.9 billion in milestones.
Via
Investor's Business Daily
Gilead's Kite, Arcellx Ink Over $300M Collaboration Pact For Late-Stage Multiple Myeloma Candidate
December 09, 2022
Via
Benzinga
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 15 Years
December 08, 2022
Via
Benzinga
Is Gilead Sciences a Buy?
December 08, 2022
This stock has got something to offer both dividend and growth investors.
Via
The Motley Fool
Expert Ratings for Gilead Sciences
December 01, 2022
Via
Benzinga
2 Reasons This Stock Could Outperform in 2023
November 30, 2022
It would be a continuation of this year's showing.
Via
The Motley Fool
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $17,000 Today
November 23, 2022
Via
Benzinga
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
December 08, 2022
-Clinical Data Due Next Week at ASH-
Via
Benzinga
Is Gilead Sciences Stock Still a Buy After Soaring in 2022?
December 08, 2022
Gilead faces some challenges. But there are several reasons to think the stock could keep the momentum going.
Via
The Motley Fool
Gilead Sciences Unusual Options Activity
December 02, 2022
Someone with a lot of money to spend has taken a bearish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly...
Via
Benzinga
Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review
December 02, 2022
The S&P 500 is fighting for its 200-day, a critical level for the uptrend.
Via
Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
December 01, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
The Top Healthcare Stocks to Buy With $100
December 01, 2022
Triple-digit growth and innovation go hand-in-hand with these companies.
Via
The Motley Fool
These 3 Stocks Are Rallying While the Rest of the Market Plunges
November 30, 2022
Sometimes an organization's growth -- and growth story -- is strong enough to overcome marketwide headwinds.
Via
The Motley Fool
Uncertainty Grips Markets-On A Clear Day Maybe You Can See A Week Ahead
November 28, 2022
Healthcare stocks are now favored by many strategists because of their defensive nature and focus on US markets.
Via
Talk Markets
Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges
November 28, 2022
Gilead and Arcus notched another win for their cancer program on Monday. GILD stock briefly hit a four-year high as RCUS stock gapped higher.
Via
Investor's Business Daily
Stocks That Hit 52-Week Lows On Thursday
December 01, 2022
During Thursday's session, 108 stocks hit new 52-week highs.
Via
Benzinga
Gilead-Arcus Biosciences Partnered Lung Cancer Therapy Shows Continuous Positive Efficacy Measures
November 28, 2022
Via
Benzinga
What Does Gilead Sciences' Debt Look Like?
November 28, 2022
Over the past three months, shares of Gilead Sciences Inc. (NASDAQ:GILD) rose by 34.80%. Before having a look at the importance of debt, let's look at how much debt Gilead Sciences has.
Via
Benzinga
Pick These 4 Stocks With Exciting Interest Coverage Ratio
November 26, 2022
Let's take a look at some of the companies that boast an impressive interest coverage ratio.
Via
Talk Markets
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
30
31
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.